These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Older melanoma patients aged 75 and above retain responsiveness to anti-PD1 therapy: results of a retrospective single-institution cohort study. Ibrahim T; Mateus C; Baz M; Robert C Cancer Immunol Immunother; 2018 Oct; 67(10):1571-1578. PubMed ID: 30056599 [TBL] [Abstract][Full Text] [Related]
8. Anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy in unresectable or metastatic mucosal melanoma: a retrospective, multicenter study of 329 Japanese cases (JMAC study). Nakamura Y; Namikawa K; Yoshikawa S; Kiniwa Y; Maekawa T; Yamasaki O; Isei T; Matsushita S; Nomura M; Nakai Y; Fukushima S; Saito S; Takenouchi T; Tanaka R; Kato H; Otsuka A; Matsuya T; Baba N; Nagase K; Inozume T; Fujimoto N; Kuwatsuka Y; Onishi M; Kaneko T; Onuma T; Umeda Y; Ogata D; Takahashi A; Otsuka M; Teramoto Y; Yamazaki N ESMO Open; 2021 Dec; 6(6):100325. PubMed ID: 34839104 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety data for checkpoint inhibitors in advanced melanoma under real-life conditions: A monocentric study conducted in Nice from 2010 to 2016. Taquin H; Fontas E; Massol O; Chevallier P; Balloti R; Beranger G; Lacour JP; Passeron T; Montaudié H Ann Dermatol Venereol; 2018 Nov; 145(11):649-658. PubMed ID: 30098818 [TBL] [Abstract][Full Text] [Related]
10. Prolonged Benefit from Ipilimumab Correlates with Improved Outcomes from Subsequent Pembrolizumab. Shreders A; Joseph R; Peng C; Ye F; Zhao S; Puzanov I; Sosman JA; Johnson DB Cancer Immunol Res; 2016 Jul; 4(7):569-73. PubMed ID: 27197063 [TBL] [Abstract][Full Text] [Related]
11. Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial. Carlino MS; Long GV; Schadendorf D; Robert C; Ribas A; Richtig E; Nyakas M; Caglevic C; Tarhini A; Blank C; Hoeller C; Bar-Sela G; Barrow C; Wolter P; Zhou H; Emancipator K; Jensen EH; Ebbinghaus S; Ibrahim N; Daud A Eur J Cancer; 2018 Sep; 101():236-243. PubMed ID: 30096704 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma. Afzal MZ; Mercado RR; Shirai K J Immunother Cancer; 2018 Jul; 6(1):64. PubMed ID: 29966520 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma. Kreft S; Gesierich A; Eigentler T; Franklin C; Valpione S; Ugurel S; Utikal J; Haferkamp S; Blank C; Larkin J; Garbe C; Schadendorf D; Lorigan P; Schilling B Eur J Cancer; 2019 Jul; 116():207-215. PubMed ID: 31212163 [TBL] [Abstract][Full Text] [Related]
14. Site-specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti-PD-1 therapy. Pires da Silva I; Lo S; Quek C; Gonzalez M; Carlino MS; Long GV; Menzies AM Cancer; 2020 Jan; 126(1):86-97. PubMed ID: 31584722 [TBL] [Abstract][Full Text] [Related]
15. Peripheral Blood TCR Repertoire Profiling May Facilitate Patient Stratification for Immunotherapy against Melanoma. Hogan SA; Courtier A; Cheng PF; Jaberg-Bentele NF; Goldinger SM; Manuel M; Perez S; Plantier N; Mouret JF; Nguyen-Kim TDL; Raaijmakers MIG; Kvistborg P; Pasqual N; Haanen JBAG; Dummer R; Levesque MP Cancer Immunol Res; 2019 Jan; 7(1):77-85. PubMed ID: 30425105 [TBL] [Abstract][Full Text] [Related]